Processa Pharmaceuticals, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Processa Pharmaceuticals, Inc. (PCSA) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$295.74 thousand for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-12-01.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2015-12-01
- Processa Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2015-09-30 was -$295.74K.
- Processa Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2015-06-30 was -$2.05M.
- Processa Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2015-03-31 was -$644.61K.
- Processa Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2014-12-31 was -$1.54M.
- Processa Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2014 was -$4.53M.
- Processa Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2013 was -$3.07M.
- Processa Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2012 was -$2.44M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 27 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 30 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 33 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 36 month |
|---|---|---|---|---|---|---|---|---|
| 2015-09-30 | -$295.74K 10-Q · filed 2015-12-01 | -$2.35M derived: sum of 2 quarters · filed 2015-12-01 | -$2.99M 10-Q · filed 2015-12-01 | -$4.53M derived: sum of 4 quarters · filed 2015-12-01 | ||||
| 2015-06-30 | -$2.05M 10-Q · filed 2015-08-19 | -$2.70M 10-Q · filed 2015-08-19 | -$4.23M derived: sum of 3 quarters · filed 2015-08-19 | -$5.03M derived: sum of 4 quarters · filed 2015-12-01 | ||||
| 2015-03-31 | -$644.61K 10-Q · filed 2015-05-15 | -$2.18M derived: sum of 2 quarters · filed 2015-05-15 | -$2.98M derived: sum of 3 quarters · filed 2015-12-01 | -$3.83M derived: sum of 4 quarters · filed 2015-12-01 | ||||
| 2014-12-31 | -$1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | -$2.33M derived: sum of 2 quarters · filed 2015-12-01 | -$3.18M derived: sum of 3 quarters · filed 2015-12-01 | -$4.53M 10-K · filed 2015-04-14 | ||||
| 2014-09-30 | -$791.95K 10-Q · filed 2015-12-01 | -$1.64M derived: sum of 2 quarters · filed 2015-12-01 | -$2.99M 10-Q · filed 2015-12-01 | -$3.79M derived: sum of 4 quarters · filed 2015-12-01 | ||||
| 2014-06-30 | -$851.22K 10-Q · filed 2015-08-19 | -$2.20M 10-Q · filed 2015-08-19 | -$3.00M derived: sum of 3 quarters · filed 2015-08-19 | -$3.72M derived: sum of 4 quarters · filed 2015-08-19 | ||||
| 2014-03-31 | -$1.34M 10-Q · filed 2015-05-15 | -$2.15M derived: sum of 2 quarters · filed 2015-05-15 | -$2.87M derived: sum of 3 quarters · filed 2015-05-15 | -$3.60M derived: sum of 4 quarters · filed 2015-05-15 | -$7.79M 10-Q · filed 2014-05-14 | |||
| 2013-12-31 | -$806.92K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | -$1.53M derived: sum of 2 quarters · filed 2015-04-14 | -$2.25M derived: sum of 3 quarters · filed 2015-04-14 | -$3.07M 10-K · filed 2015-04-14 | -$6.45M 10-K · filed 2014-03-27 | |||
| 2013-09-30 | -$718.84K 10-Q · filed 2014-11-13 | -$1.45M derived: sum of 2 quarters · filed 2014-11-13 | -$2.26M 10-Q · filed 2014-11-13 | -$3.04M derived: sum of 4 quarters · filed 2014-11-13 | -$5.64M 10-Q · filed 2013-11-08 | |||
| 2013-06-30 | -$726.57K 10-Q · filed 2014-08-19 | -$1.54M 10-Q · filed 2014-08-19 | -$2.33M derived: sum of 3 quarters · filed 2014-08-19 | -$2.93M derived: sum of 4 quarters · filed 2014-08-19 | -$4.92M 10-Q/A · filed 2013-09-06 | |||
| 2013-03-31 | -$816.37K 10-Q · filed 2014-05-14 | -$1.60M derived: sum of 2 quarters · filed 2014-05-14 | -$2.20M derived: sum of 3 quarters · filed 2014-05-14 | -$2.68M derived: sum of 4 quarters · filed 2014-05-14 | ||||
| 2012-12-31 | -$782.94K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | -$1.38M derived: sum of 2 quarters · filed 2014-03-27 | -$1.86M derived: sum of 3 quarters · filed 2014-03-27 | -$2.44M 10-K · filed 2014-03-27 | ||||
| 2012-09-30 | -$601.88K 10-Q · filed 2013-11-08 | -$1.08M derived: sum of 2 quarters · filed 2013-11-08 | -$1.66M 10-Q · filed 2013-11-08 | |||||
| 2012-06-30 | -$475.08K 10-Q/A · filed 2013-09-06 | -$1.06M 10-Q/A · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |